Velban Injection (Vinblastine Sulfate): Essential Antineoplastic Therapy – Global Supply by Ernest Oncology
In the complex landscape of 2026 oncology, Velban Injection (Vinblastine Sulfate) remains a foundational cytotoxic agent for the treatment of various malignant neoplasms. As a potent vinca alkaloid derived from the periwinkle plant, Vinblastine is critical in multi-agent chemotherapy protocols designed to achieve remission in both rare and common cancers.
Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Velban to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain maintenance and rapid global delivery.
Technical Product Profile: Velban (Vinblastine Sulfate)
Velban is supplied as a sterile, lyophilized plug or solution intended for intravenous administration. It is a cell-cycle-specific agent that arrests cellular division during the metaphase.
Product Specifications
Active Ingredient: Vinblastine Sulfate USP/BP
Common Strengths: 10 mg Vials
Pharmacological Class: Vinca Alkaloid (Antimitotic)
Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly Requires Validated Cold Chain Logistics.
Primary Clinical Indications
Hodgkin’s Disease: A core component of the ABVD regimen (Stages III and IV).
Non-Hodgkin’s Lymphoma: Utilized in various lymphocytic and histiocytic lymphoma protocols.
Testicular Cancer: Advanced germ cell tumors (often in combination with Bleomycin and Cisplatin).
Kaposi’s Sarcoma: Frequently prescribed for HIV-related or classic Kaposi's.
Letterer-Siwe Disease: Treatment of Histiocytosis X.
Breast Cancer: Used in advanced cases unresponsive to other therapies.
Mechanism of Action: Cell Cycle Disruption
Vinblastine sulfate works by interfering with the microtubule dynamics essential for cell division.
Tubulin Binding: Vinblastine binds to tubulin dimers, preventing them from assembling into microtubules.
Mitotic Spindle Inhibition: By preventing spindle formation, the cancer cell cannot separate its chromosomes during the M-phase.
Apoptosis: This mitotic arrest triggers a cascade leading to programmed cell death (apoptosis) of the malignant cells.
Global Supply Chain: UK, USA, UAE, Australia, & South Africa
Ernest Oncology specializes in navigating the strict regulatory frameworks of international pharmaceutical trade to provide uninterrupted access to oncology life-savers.
United Kingdom & London: We serve NHS Trusts and private clinics throughout London, ensuring MHRA-compliant supply and documentation.
United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Indian pharmaceutical exports.
Abu Dhabi & UAE: Supporting the Middle East's advanced medical infrastructure with fast-track, temperature-controlled shipping to the UAE.
Australia: Strategic distribution to regional wholesalers and hospitals, adhering to TGA standards.
South Africa: Strengthening the Southern African healthcare sector with affordable, high-quality cancer treatments from India.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of high-quality oncology injectables and specialized cancer care products.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
